Valuation: Control Bionics Limited

Market Cap 33.13M 23.63M 20.46M 19.35M 17.52M 32.88M 2.27B 231M 88.85M 1.15B 88.75M 86.78M 3.66B P/E 2025
-1.3x
P/E 2026 -3.78x
Enterprise Value 31.59M 22.53M 19.52M 18.45M 16.71M 31.36M 2.16B 220M 84.73M 1.1B 84.63M 82.76M 3.49B EV / Sales 2025
1.4x
EV / Sales 2026 6.07x
Free-Float
73.44%
Yield 2025 *
-
Yield 2026 -
1 week+5.17%
Current month+1.67%
1 month+3.39%
3 months-32.22%
6 months+10.91%
1 week 0.06
Extreme 0.059
0.06
1 month 0.06
Extreme 0.056
0.06
Current year 0.05
Extreme 0.05
0.1
1 year 0.03
Extreme 0.032
0.1
3 years 0.03
Extreme 0.026
0.1
5 years 0.03
Extreme 0.026
0.68
10 years 0.03
Extreme 0.026
1.24
Manager TitleAgeSince
Chief Executive Officer - 19/01/2023
Director of Finance/CFO - 13/05/2024
Chief Tech/Sci/R&D Officer - 01/01/2014
Director TitleAgeSince
Chairman 66 19/11/2025
Director/Board Member - 19/01/2023
Director/Board Member - 01/04/2023
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+5.17%+84.85%-16.44% 23.63M
+4.70%+0.21%+20.54%-31.54% 16.33B
+6.56%+16.82%-30.07%+54.23% 1.77B
-0.73%-2.78%-29.01%+17.73% 892M
-3.42%-19.43%-62.72%-85.77% 763M
+0.08%-0.03%+61.02%-1.94% 778M
-1.13%-6.14%-39.43%-50.07% 638M
-0.49%-8.87%-42.60%-52.86% 569M
-4.24%+1.93%-46.24%-41.77% 444M
0.00%-0.74%-8.52%-9.24% 393M
Average +0.09%-3.58%-9.22%-21.77% 2.26B
Weighted average by Cap. +3.48%-2.31%+8.17%-24.55%

Financials

2025 2026
Net sales 6.14M 4.38M 3.8M 3.59M 3.25M 6.1M 420M 42.84M 16.48M 213M 16.46M 16.1M 680M 4.77M 3.4M 2.94M 2.78M 2.52M 4.73M 326M 33.23M 12.78M 165M 12.77M 12.49M 527M
Net income -6.11M -4.36M -3.77M -3.57M -3.23M -6.06M -418M -42.58M -16.38M -212M -16.36M -16M -676M -7.27M -5.18M -4.49M -4.24M -3.84M -7.21M -497M -50.65M -19.49M -252M -19.46M -19.03M -804M
Net Debt -237K -169K -147K -139K -125K -235K -16.23M -1.65M -636K -8.23M -636K -621K -26.25M -1.54M -1.1M -949K -897K -812K -1.52M -105M -10.71M -4.12M -53.28M -4.11M -4.02M -170M
Logo Control Bionics Limited
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Its products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography output. This output is then sent wirelessly via NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse and the NeuroNode acts like a mouse button. It is commercializing its advancement in its technology, NeuroStrip. It is focused on neuromuscular rehabilitation and athletic optimization.
Employees
-
Date Price Change Volume
15/09/26 A$0.0610 0.00% 837,943
11/09/26 A$0.0610 +1.67% 140,006
09/09/26 A$0.0600 -3.23% 258,175
08/09/26 A$0.0620 +6.90% 214,999
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!